AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2024
Mar 14, 2024
30604_dirs_2024-03-14_7e575e3b-105e-422b-b982-c57692d4aaa4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2024-03-12
Reporting Person: Kumar Neil (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-03-12 | Stock Option (right to buy) | $28.70 | A | 45140 | Acquired | 2034-03-11 | Common Stock (45140) | Direct |
| 2024-03-12 | Restricted Stock Units | $ | A | 313588 | Acquired | Common Stock (313588) | Direct |
Footnotes
F1: 1/16th of the shares subject to this option vest and become excercsiable on May 16, 2024, and thereafter, 1/16th of the shares subject to this option will vest and become exercisable on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2024, and thereafter, 1/16th of the underlying shares will vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.